Literature DB >> 31974721

The discovery and development of rasagiline as a new anti-Parkinson medication.

John P M Finberg1.   

Abstract

Entities:  

Year:  2020        PMID： 31974721     DOI： 10.1007/s00702-020-02142-w

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN： 0300-9564            Impact factor:   3.575


× No keyword cloud information.
  25 in total

1.  Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation.

Authors:  O Sader-Mazbar; Y Loboda; M J Rabey; J P M Finberg
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

2.  Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.

Authors:  M B Youdim; A Gross; J P Finberg
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

3.  Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.

Authors:  P Riederer; M B Youdim
Journal:  J Neurochem       Date:  1986-05       Impact factor: 5.372

4.  Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO).

Authors:  Michel Panisset; Jack J Chen; Sean H Rhyee; Jill Conner; Julie Mathena
Journal:  Pharmacotherapy       Date:  2014-10-14       Impact factor: 4.705

5.  Some puzzling pharmacological effects of monoamine oxidase inhibitors.

Authors:  J Knoll; K Magyar
Journal:  Adv Biochem Psychopharmacol       Date:  1972

Review 6.  Selective inhibitors of monoamine oxidase A and B: biochemical, pharmacological, and clinical properties.

Authors:  C J Fowler; S B Ross
Journal:  Med Res Rev       Date:  1984 Jul-Sep       Impact factor: 12.944

7.  Interactions between sympathomimetic amines and a new monoamine oxidase inhibitor.

Authors:  M H Lader; G Sakalis; M Tansella
Journal:  Psychopharmacologia       Date:  1970-08-19

8.  The effect of age on the activity and molecular properties of human brain monoamine oxidase.

Authors:  C J Fowler; A Wiberg; L Oreland; J Marcusson; B Winblad
Journal:  J Neural Transm       Date:  1980       Impact factor: 3.575

9.  Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B.

Authors:  J P Finberg; M Tenne; M B Youdim
Journal:  Br J Pharmacol       Date:  1981-05       Impact factor: 8.739

10.  Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours.

Authors:  John P M Finberg; Moussa B H Youdim
Journal:  Neuropharmacology       Date:  2002-12       Impact factor: 5.250
View more
  2 in total

1.  Pharmacokinetics and Bioequivalence of Rasagiline Tablets in Chinese Healthy Subjects Under Fasting and Fed Conditions: An Open, Randomized, Single-Dose, Double-Cycle, Two-Sequence, Crossover Trial.

Authors:  Yinjuan Li; Lu Qi; Haihong Bai; Ying Liu; Rongxia Fan; Yongrui Tu; Yongqiang Sun; Juxiang Wang; Qi Qi; Xiaohui Feng; Da Zhou; Xinghe Wang
Journal:  Front Pharmacol       Date:  2020-12-03       Impact factor: 5.810

Review 2.  The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know.

Authors:  David S Goldstein
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.